Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Does anyone else find it hilarious that The Honorable Richard G. Andrews would waste the courts time and money since September 21, 2015, only to throw the case out now because he dislikes patent trolls LOL!!!!!
Long UOIP,
~Magnus
Zomby,
I plan on attending the hearing. Is this the correct address?
J. Caleb Boggs Federal Building
844 N. King Street
Wilmington, DE 19801-3555
Courtroom: 6A
November 25, 2019
3pm EST
https://www.ded.uscourts.gov/judge/judge-richard-g-andrews
https://www.ded.uscourts.gov/sites/ded/files/pages/Court_Calendar.pdf
Long UOIP,
~Magnus
I will take this one for a ride. No stop signs or warnings, and a huge amount of upward potential. This is a good long investment.
Go GOVX!!!
~Magnus
Cellgenic Set to Open New Stem Cells Center in Belgium through Partnership with Churchill Aesthetic Center
Industry: Healthcare
The subsidiary of the Global Stem Cells Group seeks to meet the growing demand for patients seeking stem cells treatments across the globe
Miami Lakes, FL (PRUnderground) September 25th, 2019
Cellgenic, a subsidiary of the Global Stem Cells Group (GSCG), has announced that it has signed an agreement that will bring regenerative medical treatments to more patients across Europe with the opening of a new stem cells treatment center in Belgium.
The agreement, signed between the GSCG and Dr. Samy Joheir, owner of Churchill Aesthetic Center (https://www.churchill-aesthetic-center.be/), expands the GSCG’s mission of expanding access to regenerative medicine globally. The agreement opens the center’s doors to patients seeking stem cells treatment options and to physicians across Europe and the Middle East seeking educational opportunities regarding how to incorporate regenerative medicine into their practices. The center is located at 141 Winston Churchill Avenue, B-1180 in Brussels.
The Brussels center will also serve as the GSCG’s head offices and will help the group better serve patients and doctors across Europe and the Middle East.
To new center will officially open on September 30, 2019. In conjunction with the center’s opening, the GSCG and Dr. Joheir will welcome three patients from the Middle East seeking treatments offered by the center. These patients were previously treated in the US prior to the institution of stricter FDA stem cells regulations. The Belgium center will provide these patients with treatment options closer to home, alleviating emotional, financial, and physical stressors in receiving treatment, similar to the group’s current facilities in Cancun that provide critical stem cells treatment to patients traveling from the US.
With the opening of the center, the GSCG also aims to provide more accessible educational facilities and options for physicians in the region looking to receive training in regenerative medicine. The training is in alignment with the services currently offered at the GSCG’s other facilities, such as those located in Cancun for physicians across the Americas.
Over the past few years, the GSCG has sought to achieve its mission in helping to alleviate human suffering by opening stem cells centers across the globe to meet growing patient demands. All of the group’s centers are all currently located outside of the US due to current FDA regulations restricting regenerative medicine products and protocols.
“The Global Stem Cells Group is pleased to be able to reach more patients seeking relief through regenerative medicine with the opening of our Belgian center,” said Benito Novas, CEO of the Global Stem Cells Group. “This expansion will help alleviate travel and financial barriers some European and Middle Eastern patients face in receiving the care they need, now providing them access to a facility closer to home. We are committed to opening up additional treatment centers for both physicians and patients across the globe who may be limited by their local regulations in accessing critical stem cells therapies. Through our facilities, patients looking for relief from regenerative diseases will receive top-notch care in state-of-the-art facilities.”
To learn more about the Global Stem Cells Group and its latest efforts, visit http://www.stemcellsgroup.com/.
About Global Stem Cells Group
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.
Didn't lose money, I lost liquidity.
What a joke, Sydney you trashed this stock. Go back to playing tennis.
Thanks for nothing Sydney. Not what I expected from a OTCQB
Magnus
Difference of 66,314,713 on the OS approx $119,366.48 at $0.0018
NTRR Neutra Corp.
OTCQB Member Since 03/2015
As of 09/09/2019
A/S ??
O/S 257,533,491
Restricted 20,095,990
Unrestricted 237,437,501
Held at DTC 237,115,081
Float 37,127,496 as of 06/11/2019
=========================================
As of 8/5/2019
A/S 480,000,000
O/S 191,218,778
Restricted 20,095,990
Unrestricted 171,122,788
Held at DTC 157,758,550
Float 37,127,496 as of 06/11/2019
I ask because let’s assume Lans Holding had the updated financials 9/12 or close to being ready. Then theoretically they could secure a MM and have forms drawn up.
OR
Lans Holdings records are a can of worms they do not want opened and they now need time to make a fresh start and merge with Global Stem Cell Group. Together running the business and submitting good records to the SEC
Isn’t 180 days just a arbitrary number and they could finish before hand?
Good find MjMilo
Long UOIP,
~Magnus
CBDNewsBreaks – Neutra Corp. (NTRR) CEO Discusses CBD as Chronic Pain Treatment
Early-stage research and development company Neutra Corp.’s (OTCQB: NTRR) CEO Sydney Jim recently discussed the company’s activities in an interview with NetworkNewsWire (http://cnw.fm/b07SI). A recent article discussing the interview reads, “Jim, a former professional tennis player, emphasized the company’s motivation to help the next generation of athletes with pain management. During the interview, he talks about dealing with pain, not only as a former professional athlete but, on an occasion as recent as last year, when he suffered multiple severe injuries and broken bones as a result of an accident. . . . Jim knows the benefits of hemp-based products firsthand, and CBD may offer an option for treating different types of chronic pain. A study cited by Harvard University showed that CBD applied on the skin could help lower pain and inflammation due to arthritis (http://cnw.fm/q4dD5). Other research demonstrated the mechanism by which CBD inhibits inflammatory and neuropathic pain — two of the most difficult types of chronic pain to treat.”
To view the full article, visit http://cnw.fm/cMz0S
About Neutra Corp.
Neutra Corp. is an early-stage research and development company committed to bringing modern, healthy-living solutions to a multibillion-dollar market. Cutting-edge technologies within the nutraceuticals, food and drug, and environmental purification sectors are creating a new kind of world culture — one where consumers are demanding access to products that promote health and stave off potential health dangers. One of the nutraceutical submarkets is the new, thriving, hemp-based CBD market, in which the company intends to participate. For more information, visit the company’s website at www.Neutrainc.com.
NOTE TO INVESTORS: The latest news and updates relating to NTRR are available in the company’s newsroom at http://cnw.fm/NTRR
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com
Outstanding DD on LAHO/GSCG
It is obvious how much time and effort you have put into searching and preparing this.
Thank you and continued long LAHO,
~Magnus
I like your idea Rockie, and look forward to hearing what you learn about Billy's office.
Long UOIP,
~Magnus
Lans Holdings Secures Extension to Complete Acquisition of Global Stem Cells Group
Industry: Healthcare
Lans Holdings Inc. is pleased to announce that it has successfully secured a 180-day extension to complete the acquisition of 100% of Global Stem Cells Group Inc (GSCG)
Miami Lakes, FL (PRUnderground) September 13th, 2019
On Friday September 6, 2019, trading in the company’s stock was suspended due to a missed communication regarding the pending delinquent annual filings. Company management has had several discussions with the SEC and has determined that an old address is the cause for the missing paperwork. The Company has agreed to enter into a settlement with the SEC, which will result in the deregistering of the Company’s shares. Company management had been working with its auditors, accounting staff and outside consultants for the past few months to bring the Company’s filings current when the Company learned of the revocation. The Company intends to now file a form 10 to reregister its common shares with the SEC and to locate a market maker to sponsor the Company in a 211 filing to reinstate trading of the Company’s shares.
“We regret the concern this put on the market, and especially the delay in communication of these events, as we had to ensure that we had accurately secured all of the necessary agreements to successfully recover from this disruption,” said Dave Christensen, CEO of Lans Holdings. “We have been working diligently on catching up all records and we are looking forward to quickly submitting a Form 10, and then closing the acquisition.”
This press release should be read in conjunction with all other filings on www.sec.gov
For more information on Global Stem Cells Group please visit: www.stemcellsgroup.com
About Global Stem Cells Group
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.
Dear Investor,
Thank you for your patience during this temporary disruption. We regret the concern this put on the market, and especially the delay in communication of these events, as we had to first ensure that we had accurately secured all of the necessary agreements before we could communicate anything.
We hope by now you have read our official Press Release https://finance.yahoo.com/news/lans-holdings-secures-extension-complete-130000269.html?.tsrc=fin-srch
In our Press Release we clarified 4 key steps that Lans Holdings Inc is working on
- Finish getting our past filings to date (which we have already been working on)
- File a form 10 to reregister its common shares with the SEC
- Secure a Market Maker to sponsor the Company in a 211 filing to reinstate trading of the Company’s shares
- Complete the Acquisition of GSCG
All of this information is public information and therefore does not violate any SEC regulations with regards to sharing unique information with any individual investor.
Best regards,
Investor Relations
LAHO
Thank you for the information on Naked Short Sales. That helps clear things up
~Magnus
It's my opinion as to what's being done to this and countless other stocks. I have no idea who to report this to, nor can i prove it :/
I do my best to stay ahead of those people that assist in naked shorts
~Magnus
This is an attack on LAHO
The objective of a “naked short” attack is to drive a company’s stock price to the lowest prices possible and keep that stock price at that level with the hopes a company never recovers in value. This strategy in this illegal shorting allows the criminality to continue unchecked, raping millions upon millions of dollars out from the financial system.
Help me understand how LAHO screwed its investors?
~Magnus
LAHO is keeping us informed. Read the press release and next we are back to trading.
https://www.globenewswire.com/Search?organization=Lans%20Holdings%20Inc.
nicehit wrote:
Friday, 09/06/19 09:53:48 AM
Post # 51087of 51107
No worries... the fillings are in the process of getting done. This RM is big, the process is tedious to get current, lots of dot the I's and cross the T's.
They need to PR with current status, if not then something is wrong.
Big drop when open... then big pop if all is still on course.
MIAMI, FL, Sept. 11, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Lans Holdings Inc. is pleased to announce that it has successfully secured a 180-day extension to complete the acquisition of 100% of Global Stem Cells Group Inc (GSCG).
On Friday September 6, 2019, trading in the company’s stock was suspended due to a missed communication regarding the pending delinquent annual filings. Company management has had several discussions with the SEC and has determined that an old address is the cause for the missing paperwork. The Company has agreed to enter into a settlement with the SEC, which will result in the deregistering of the Company’s shares. Company management had been working with its auditors, accounting staff and outside consultants for the past few months to bring the Company’s filings current when the Company learned of the revocation. The Company intends to now file a form 10 to reregister its common shares with the SEC and to locate a market maker to sponsor the Company in a 211 filing to reinstate trading of the Company’s shares.
“We regret the concern this put on the market, and especially the delay in communication of these events, as we had to ensure that we had accurately secured all of the necessary agreements to successfully recover from this disruption,” said Dave Christensen, CEO of Lans Holdings. “We have been working diligently on catching up all records and we are looking forward to quickly submitting a Form 10, and then closing the acquisition.”
This press release should be read in conjunction with all other filings on www.sec.gov
For more information on Global Stem Cells Group please visit: www.stemcellsgroup.com
About Lans Holdings Inc.
Lans Holdings offers payment solutions. The Company makes it easy for sellers to start selling, and buyers to buy with confidence. The Company plans to process credit card payments online. In time, the Company hopes to be known in the industry as a secure and reliable source of payment processing. With the Company's breadth of business structure experience and technology consultants, the Company aims to help projects and companies grow.
Further information on the Company can be found at www.sec.gov and the company's website at www.lans.holdings
Forward Looking Statements
Some information in this document constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements, such as the closing of the share exchange agreement. The words “plan”, "forecast", "anticipates", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Lans Holdings Inc., herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Lans Holdings Inc. disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
For further information, please contact:
investors@lans.holdings
Telephone: +1.786.789.5758
Glass half full
nicehit wrote:
Friday, 09/06/19 09:53:48 AM
Post # 51087of 51107
No worries... the fillings are in the process of getting done. This RM is big, the process is tedious to get current, lots of dot the I's and cross the T's.
They need to PR with current status, if not then something is wrong.
Big drop when open... then big pop if all is still on course.
Guilty with an explanation - On July 24, 2019, the Company dismissed GBH CPAs, PC (the “Former Accountant”). They are working towards a fix.
Quote:
SECTION 4- Matters Related to Accountants and Financial Statements
Item 4.01 Changes in Registrant’s Certifying Accountant.
On July 24, 2019, the Company dismissed GBH CPAs, PC (the “Former Accountant”) as the Company’s independent registered public accounting firm and on July 24, 2019, the Company engaged Fruci & Associates II, PLLC (the “New Accountant”) as the Company’s independent registered public accounting firm. The engagement of the New Accountant was approved by the Company’s Board of Directors.
The Former Accountant’s audit reports on the financial statements of the Company for the fiscal years ended November 30, 2016 and 2015 contained no adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principles, except that the audit reports on the financial statements of the Company for the fiscal years ended November 30, 2016 and 2015 contained an uncertainty about the Company’s ability to continue as a going concern.
During the fiscal years ended November 30, 2016 and 2015, and through the interim period ended July 24, 2019, there were no “disagreements” (as such term is defined in Item 304 of Regulation S-K) with the Former Accountant on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements if not resolved to the satisfaction of the Former Accountant would have caused them to make reference thereto in their reports on the financial statements for such periods.
During the fiscal years ended November 30, 2016 and 2015, and through the interim period ended July 24, 2019, there were the following “reportable events” (as such term is defined in Item 304 of Regulation S-K). As disclosed in Part I, Item 4 of the Company’s Form 10-Q for the quarter ended September 30, 2018, the Company’s management determined that the Company’s internal controls over financial reporting were not effective as of the end of such period due to the existence of material weaknesses related to the following:
(i) inadequate segregation of duties and effective risk assessment; and
(ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines.
These material weaknesses have not been remediated as of the date of this Current Report on Form 8-K.
Other than as disclosed above, there were no reportable events during the fiscal years ended November 30, 2016 and 2015, and through the interim period ended July 24, 2019. The Company’s Board of Directors discussed the subject matter of each reportable event with the Former Accountant. The Company authorized the Former Accountant to respond fully and without limitation to all requests of the New Accountant concerning all matters related to the audited period by the Former Accountant, including with respect to the subject matter of each reportable event.
Prior to retaining the New Accountant, the Company did not consult with the New Accountant regarding either: (i) the application of accounting principles to a specified transaction, either contemplated or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements; or (ii) any matter that was the subject of a “disagreement” or a “reportable event” (as those terms are defined in Item 304 of Regulation S-K).
On July 26, 2019, the Company provided the Former Accountant with its disclosures in the Current Report on Form 8-K disclosing the dismissal of the Former Accountant and requested in writing that the Former Accountant furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether or not they agree with such disclosures. The Company plans to update this Current Report on Form 8-K and attach the letter from the Former Accountant once received.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Lans Holdings Inc.
/s/ David Christensen
David Christensen
Chief Executive Officer
Date: July 29, 2019
I agree 100%
nicehit wrote:
Friday, 09/06/19 09:53:48 AM
Post # 51087of 51107
No worries... the fillings are in the process of getting done. This RM is big, the process is tedious to get current, lots of dot the I's and cross the T's.
They need to PR with current status, if not then something is wrong.
Big drop when open... then big pop if all is still on course.
8K Released merger/acquisition is official
ITEM 2.01. Completion of Acquisition or Disposition of Asset
Effective August 30, 2019, Neutra Corp. (the “Company”, “we”, “our”) entered into an agreement to purchase all of the outstanding stock of Vivis Corporation, a Wyoming corporation, (“Vivis”) from Sydney Jim, the Company’s CEO. The purchase price for Vivis is $35,000 cash and a royalty of 40 percent of gross revenue until $100,000 is paid declining to 25 percent until an additional $100,000 has been paid. There will be a 10 percent royalty in perpetuity. Since this transaction involves our CEO, it will be accounted for as a related party transaction.
NTRR’s CEO Sydney Jim was a co-founder of the brand VIVIS which they have been working diligently on creating a brand that would be highly represented in the Professional and Amateur Sports Market. The initial launch product is a 25mg CBD soft gel which is the most efficient ingestion delivery system. VIVIS prides itself on the education on how to utilize the proper methods of CBD delivery systems for it’s customers. NTRR was lacking a CBD product to the market, so VIVIS was the perfect fit considering the time and effort already put in prior to Mr. Jim joining NTRR.
https://www.sec.gov/Archives/edgar/data/1512886/000116169719000366/form_8-k.htm
That was a long phone call, but none the less I got my order in. Hopefully better than my luck with $LAHO and $NTRR
~Magnus
e-trade would not let me buy? something going on with this?
Many stock have traded well in the grey
No slump with that last minute buy of 5.6M shares at $0.00296
$NTRR
Trading volume today of 42,328,494
This is great considering the O/S of 191,218,778
$$NTRR$$
The new twitter looks good, I have followed.
https://twitter.com/CorpNeutra
$$NTRR$$
1M shares will buy everything up to 38
$NTRR is moving up from here
ByJim BloomPosted on September 5, 2019
Neutra Corp (OTCMKTS: NTRR) is banking on a rapid expansion drive in the hemp industry to reinvigorate its growth prospects. The company has shifted its focus from the nutraceutical market to focus on the hemp-based cannabidiol CBD market.
The announcement that the company is on its way to becoming a vertically integrated company focused on cultivation, manufacturing, and formulation of hemp products explains why the stock has started surging.
NEUTRA CORP PRICE ANALYSIS
The stock has bottomed out from all-time lows on the back of high turnover in traded shares. The bounce-back signals renewed investor interest as the company moves to pursue opportunities in the multi-billion-dollar CBD industry. A move to acquire Vivis, an emerging retail brand on hemp-based health and nutritional products all but affirms the company’s push for growth.
While the stock has shed more than 80% in market value since the start of the year, improving underlying fundamentals, continue to fuel a bounce back. Price action activity indicates Neutra Corp is making a run for the $0.01 psychological level.
NTRR Daily Chart
The stock needs to rally and find support above the $0.01 level to affirm its break out credentials after the recent slump. A rally followed by a close above the $0.02 level could give bulls a reason to come back in ahead of the stock making a run for the $0.04 level.
WHAT DOES NEUTRA CORP DO?
Neutra Corp casts itself as an early-stage research and development company. The company is focused on innovative technologies within the Nutraceuticals, food, drug, and environmental purification industry. In the recent past, the company has diversified its business empire in pursuit of opportunities in the hemp industry.
HEMP INDUSTRY OPPORTUNITY
Neutra Corp has started bottoming out from all-time lows on making it clear that its future lies in the hemp industry. A shift of focus from Nutraceutical opens the door for the company to flex its muscle on the sale of hemp-based products whose market size could reach $22 billion over the next three years.
In pursuit of opportunities on the sale of hemp-based products, Neutra Corp is planning to become a vertically integrated company focused on cannabis cultivation, manufacturing and formulation of products.
According to the Chief Executive Officer, Sydney Jim, plans are underway to come up with quality and potent products to meet growing demand in the hemp industry. The company is also in the process of developing business networks that will help support its hemp-based CBD products made up of supplements and creams.
HEMP-FOCUSED ACQUISITION
The signing of letter intent for the acquisition of Vivis further affirms how committed the company is about opportunities in the hemp industry. The Chief Executive officer expects Vivis to provide Neutra Corp a greater market presence in the hemp industry.
“Vivis’ hemp-derived CBD (cannabidiol) products are third-party certified as containment-free and of consistent quality and potency. Consumers are increasingly looking for this certification when they buy hemp-based CBD products. With Vivis as the new retail face of Neutra, we’re expecting greater interest in the other products we’re bringing to market,” Explained Mr. Jim.
The acquisition of Vivis comes hot on the heels of Neutra Corp inking deal to acquire J3 holdings. With the acquisition, the company further strengthened its prospects into becoming a vertically integrated hemp focused company.
J3 Holdings provides Neutra Corp with access to a robust cannabis cultivation operation. In addition, the company also owns a warehouse as well as licenses for the processing of hemp.
“This is a big acquisition and a great demonstration of the continued evolution of our company. This shows we are moving forward with our plans to become a serious player in the ever-growing CBD market. CBD products are rapidly gaining mainstream acceptance said at the time,” said Mr. Jim at the time.
BOTTOM LINE
While Neutra Corp poor market performance over the past year is a point of concern, the future is certainly looking brighter now. The company has shown it has what it takes to become a vertically integrated cannabis player. The acquisition of Vivis and J3 Holdings all but signals the company is more than ready to spend some cash all in the effort of strengthening its position in the booming CBD market.
Neutra Corp appears to have hit a bottom as it has started to correct higher. The stock rallying and finding support above the $0.01 mark should affirm its break out credentials. Overall, NTRR looks to be a discount entry opportunity at current levels.
We will be updating our subscribers as soon as we know more. For the latest updates on NTRR, sign up below!
Disclosure: We have no position in NTRR and have not been compensated for this article.
RELATED ITEMS:FEATURED, NEUTRA CORP, NEUTRA CORP. (OTCMKTS:NTRR), OTCMKTS:NTRR
Guess who's back... NTRR is back o.O
Feels so empty without NTRR
Green at $0.0034 and a volume of 22M at 11:10am EST
$NTRR looking for a strong green day!!
Neutra Corp. (NTRR) is “One to Watch”
- Sports performance medicine and nutrition is a strong focus for Neutra. As the company’s new Sports Performance Medical Advisor, Dr. Cherry will continue his recent work designing tailored medical programs and services focused on human performance.
- Neutra will aggressively target the promising sports nutrition market, a segment with sales that are currently expected to reach $11 billion by 2023.
- Neutra is developing third-party certified hemp-derived CBD health and nutritional product lines for consumers.
- Hemp-based CBD consumer projects generated sales of up to $390 million in 2018 with analysts predicting sales of hemp-based products could reach $22 billion by 2022.
- Leadership has a proven track record of adding value for public company shareholders.
Neutra Corp. (OTCQB: NTRR) is an early-stage research and development company bringing modern healthy living solutions to a multi-billion-dollar market. Cutting-edge technologies within the nutraceuticals, food and drug, and environmental purification sectors are creating a new kind of world culture – one where consumers are demanding access to products that promote health and stave off potential health dangers.
Neutra is concentrating on developing into a vertically integrated company able to cultivate, manufacture and distribute hemp-based cannabidiol (CBD) products. Hemp-based CBD consumer products generated sales of up to $390 million in 2018 with projections pointing to a $3 billion market by 2022, according to the Hemp Business Journal.
Neutra’s new broadened scope, which includes the commercialization of newer, more effective products, aims to capitalize on this worldwide boom. Our company is seeking new and exciting opportunities that can accelerate Neutra’s mission to bring these products to a wider demographic. Our work reflects a renewed dedication to supporting a better body, environment and life for people around the globe.
Acquisitions
- Vivis – Neutra is expanding its market presence in the rapidly growing hemp-derived CBD market with a letter of intent to acquire Vivis, an emerging retail brand of hemp-based health and nutritional products. Vivis’ hemp-derived CBD products are third-party certified as contaminant-free and of consistent quality and potency. Consumers are increasingly looking for this certification when they buy hemp-based CBD products. With Vivis as the new retail face of Neutra, the company is expecting greater interest in its expanding portfolio of branded products moving to market.
- J3 Holdings – The signing of a letter of intent to acquire J3 Holdings includes the company’s land and warehouse, as well as a license to cultivate hemp and refine it into usable forms. Neutra has concentrated its early efforts developing business networks and on developing hemp-based CBD products, including supplements and creams. The latest move will enable the company to grow its own hemp supply, giving it more control over the quality of its ingredients.
Partners
- Surface to Air Solutions is the North American distributor of a patent-pending, water-based solution known as Purteq, a green technology that works similar to photosynthesis.
- ZeroBlast uses a durable, non-toxic, anti-microbial solution to eliminate all contaminates and kill germs on contact for a period of up to 90 days.
Leadership
Neutra president and CEO Sydney Jim provides strong executive leadership, a network of business contacts and experience implementing solid corporate strategy. Jim has a proven track record of adding value for public company shareholders. He founded Global Visionary Investments where operational support is provided to seven different companies and their subsidiaries. Jim was also the CEO of First Titan Energy, a microcap public company where he was responsible for restructuring the corporate structure, deal sourcing, and leading the company in mergers and acquisitions.
Dr. Scott Cherry is the company’s sports performance medical advisor. He is an energetic physician executive with a passionate focus on health, performance and prevention. Dr. Cherry received emergency medical technician training in the U.S. Navy, a bachelor’s degree in chemistry from Florida State University, medical degree from Nova Southeastern University, and a master’s degree of public health from Uniformed Services University F. Edward Herbert School of Medicine. Dr. Cherry has honed his skills in a variety of medical and executive positions spanning the U.S. Army and Navy, several Fortune 500 corporations, and major health care facilities over the past 20 years.
For more information, visit the company’s website at www.NeutraInc.com
NOTE TO INVESTORS: The latest news and updates relating to NTRR are available in the company’s newsroom at http://nnw.fm/NTRR
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Great job work-n-hard!!!
$$NTRR$$
Looking for another green day!! Make this 4 days in a row
$$NTRR$$